Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

319
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
319

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficient treatment of surfactant containing wastewater by photocatalytic ozonation with BiPO<sub>4</sub> nanorods.

Chemosphere·2023
Same author

Nanoporous two-dimensional MoS2 membranes for fast saline solution purification.

Physical chemistry chemical physics : PCCP·2016
Same author

Nonlinear Connectivity in the Human Stretch Reflex Assessed by Cross-Frequency Phase Coupling.

International journal of neural systems·2016
Same author

Codon identity regulates mRNA stability and translation efficiency during the maternal-to-zygotic transition.

The EMBO journal·2016
Same author

Population data of 15 autosomal STR loci in Chinese Han population from Jiangsu Province, Eastern China.

Forensic science international. Genetics·2016
Same author

Expression of Bcl-2 genes in channel catfish after bacterial infection and hypoxia stress.

Developmental and comparative immunology·2016

Related Experiment Video

Updated: May 24, 2025

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

201

A nomogram for predicting cancer-specific survival in patients with locally advanced unresectable esophageal cancer:

Liangyun Xie1, Yafei Zhang1, Xiedong Niu1

  • 1The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, China.

Frontiers in Immunology
|March 3, 2025
PubMed
Summary

A new nomogram accurately predicts cancer-specific survival for esophageal cancer patients, outperforming traditional staging. This tool aids in managing locally advanced, unresectable cases, improving treatment strategies.

Keywords:
LASSO regressionSEERcancer-specific survival (CSS)immune microenvironmentlocally advanced esophageal cancerprognostic nomogram

More Related Videos

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.1K
Development of Compendium for Esophageal Squamous Cell Carcinoma
03:36

Development of Compendium for Esophageal Squamous Cell Carcinoma

Published on: April 12, 2024

362

Related Experiment Videos

Last Updated: May 24, 2025

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

201
Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.1K
Development of Compendium for Esophageal Squamous Cell Carcinoma
03:36

Development of Compendium for Esophageal Squamous Cell Carcinoma

Published on: April 12, 2024

362

Area of Science:

  • Oncology
  • Cancer Prognostics
  • Medical Informatics

Background:

  • Esophageal cancer, especially locally advanced unresectable types, has a poor prognosis despite immunotherapy advances.
  • Current staging systems like the American Joint Committee on Cancer (AJCC) staging inadequately predict patient outcomes.
  • There is a critical need for improved prognostic tools in esophageal cancer management.

Purpose of the Study:

  • To develop and validate a nomogram for predicting cancer-specific survival (CSS) in patients with locally advanced unresectable esophageal cancer.
  • To compare the predictive accuracy of the developed nomogram against the traditional AJCC staging system.

Main Methods:

  • Utilized clinicopathological and survival data from the Surveillance, Epidemiology, and End Results (SEER) database (2010-2021).
  • Employed Least Absolute Shrinkage and Selection Operator (LASSO) regression to identify 10 key prognostic factors.
  • Constructed and validated a nomogram using training (70%) and validation (30%) cohorts, assessing performance with C-index, AUC, NRI, and IDI.

Main Results:

  • The nomogram identified 10 significant prognostic factors including age, marital status, tumor characteristics, and treatment modalities.
  • The nomogram demonstrated robust predictive performance with a C-index of 0.660 (training) and 0.653 (validation).
  • The nomogram significantly outperformed the AJCC staging system in predicting prognosis, as indicated by calibration plots and decision curve analysis.

Conclusions:

  • A validated nomogram effectively predicts cancer-specific survival in locally advanced unresectable esophageal cancer.
  • The nomogram offers superior predictive accuracy compared to the AJCC staging system.
  • Future models should incorporate biomarkers like PD-L1 and TMB to enhance prognostic capabilities in the era of immunotherapy.